On the stock market since 2012, it operates in the world of health and science. It has 60 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $27.8M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
The net profit margin is 21% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 15% a year on average.
There is $28.6M in the vault; even if every debt were paid off, $27.8M would remain.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
The price action doesn’t yet back an upward turn. Council score: 3/10.
On our five-subject report card, BIOYF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BIOYF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.